Bacterial infections such as febrile urinary tract infection (fUTI) may run a complicated course which is difficult to foretell on clinical evaluation only. Because the conventional biomarkers erythrocyte sedimentation rate (ESR), leukocyte count, C-reactive protein (CRP) and procalcitonin (PCT) have a limited role in the prediction of a complicated course of disease, a new biomarker -plasma midregional pro-adrenomedullin (MR-proADM) -was evaluated in patients with fUTI. We conducted a prospective multicentre cohort study including consecutive patients with fUTI at 35 primary care centres and 8 emergency departments. Clinical and microbiological data were collected and plasma biomarker levels were measured at presentation to the physician. Survival was assessed after 30 days. Of 494 fUTI patients, median age was 67 [IQR 49-78] years, 40% were male; two third of them had significant co-existing medical conditions. Median MR-proADM level was 1.42 [IQR 0.67-1.57] nmol/L; significantly elevated MR-proADM levels were measured in patients with bacteraemia, those admitted to the ICU, and in 30-and 90-day non-survivors, as compared to patients without these characteristics. The diagnostic accuracy for predicting 30-day mortality in fUTI, reflected by the area-under-the-curve of receiver operating characteristics were: MR-proADM 0.83 (95%CI: 0.71-0.94), PCT 0.71 (95%CI: 0.56-0.85); whereas CRP, ESR and leukocyte count lacked diagnostic value in this respect. This study shows that MR-proADM assessed on first contact predicts a complicated course of disease and 30-day mortality in patients with fUTI and in this respect has a higher discriminating accuracy than currently available biomarkers ESR, CRP, PCT and leukocyte count.
Introduction
Urinary tract infections (UTIs) are one of the most common bacterial infections. Febrile UTI (fUTI), reflecting acute pyelonephritis, prostatitis or urosepsis, is a potentially serious infection with a mortality rate of about 0.3%, but in bacteremic fUTI the mortality may be as high as 7.5-30% (1;2). Moreover, bacteraemia in fUTI is associated with prolonged hospitalization and a complicated course (3) (4) (5) , and occurs in up to 30% of those admitted to hospital and in 15% of patients treated at home (6) . Evaluation of clinical symptoms fails to provide accurate guidance to the clinician which patients have bacteraemia or who may run a complicated course, and which patients may be safely treated at home. At present, there is a lack of robust inflammatory biomarkers that may help determine severity of disease in fUTI (7;8) . A promising new biomarker is midregional pro-adrenomedullin (MR-proADM).
Adrenomedullin (ADM) has been detected in a variety of tissues including kidneys. It has immune modulating, metabolic and bactericidal activity, and is involved in regulation of complement activity (9) (10) (11) (12) . Reliable plasma measurement of ADM is challenging due to half-life time of 22 minutes (13) .
MR-proADM, the more stable mid-regional fragment of adrenomedullin, has been identified in plasma of patients with septic shock (13) (14) (15) .
The aim of the present study is to assess the prognostic value of plasma MR-proADM in adult patients with fUTI with respect to bacteraemia, need for hospital admission and a complicated course, as compared to current available biomarkers like blood leukocyte count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and procalcitonin (PCT).
Patients and methods
We conducted a prospective observational multicentre cohort study of patients presenting with a presumptive diagnosis of fUTI from January 2004 until March 2011. Participating centres were 35 primary care centres and 8 emergency departments (ED) in the Netherlands as described previously (6, 8) . The local ethics committees approved the study and all participants provided written informed consent. Over 7 years, we established a cohort of 869 patients. From this database, we randomly selected (every other patient, e.g. the 1 st , 3 rd ,5 th , etc.) frozen plasma samples of 494 patients for measurement of MR-proADM.
Inclusion criteria were age ≥18 years, fever (≥38.0 °C) and/or a history of fever or shaking chills within 24 hours before presentation, at least one symptom of UTI (dysuria, perineal pain or flank pain) and a positive nitrite dipstick test or leucocyturia. Exclusion criteria were current treatment for urolithiasis or hydronephrosis, pregnancy, hemo-or peritoneal dialysis, history of kidney transplantation or presence of polycystic kidney disease.
Patients were only included once.
Procedures and definitions
Clinical data and laboratory values were collected within 24 hours of enrolment by standardized questionnaires and reviewing the medical record. All patients were empirically treated with antibiotics according to local and national policy. Blood cultures and clean midstream-catch urine cultures were obtained before starting antimicrobial therapy and analysed using standard microbiological methods. Bacteraemia was defined as growth of any pathogen in the blood culture, except coagulase-negative staphylococci.
Plasma ethylenediaminetetraacetic acid (EDTA) blood samples were collected, centrifuged and stored at -80 °C within two hours of patient enrolment. MR-proADM and PCT levels were measured after completion of all study enrolments, using a Time Resolved Amplified Cryptate Emission technology assay (TRACE®, Kryptor Compact, MR-proADM sensitive and PCT sensitive; Thermofisher -Brahms AG; Henningsdorf, Germany). The median concentration of MR-proADM in a cohort of healthy individuals was 0.39 nmol/L (97.5 th percentile: 0.55 nmol/L) (16) . According to the manufacturer recommendation we tested MR-proADM levels for different cut-off values (16;17) . Results of PCT measurement to predict bacteraemia have been described previously (8) . Measurements of CRP, ESR and leukocyte count were only done at enrolment when indicated by the attending physician. All End points MR-proADM values were evaluated for their predictive acumen of primary and secondary endpoints, in comparison to that of the other biomarkers. The primary endpoint was 30-day mortality. Secondary endpoints were presence of bacteraemia at admission, need for hospital admission as estimated by the Acute Pyelonephritis Severity Index score (APSI score), and need for ICU admission. The APSI score is a prediction rule allocating points to age, sex, nursing home residency, comorbidities, and vital signs at presentation (18) .
Statistical analysis
The histogram of biomarker values were skewed and log-normalized before analysis. Descriptive analysis included means with confidence intervals (CIs) or medians and ranges, as appropriate. Univariate analysis was performed using ANOVA, student's t-test or where appropriate Mann-Whitney U-test for continuous variables and Chi-square tests for categorical variables. Continuous variables were added into the models as continuous variables (except for the APSI-score) and log-normalized if data were not normal distributed. The APSI-score was analysed as a binary variable, using a cut-off value of 100 points, based on previous data (18) . 
Results
In total 494 patients were randomly selected from our existing database resource. There were no significant differences between our study population and the remainder of the database population, except for having a significantly older population (p=0.027) with significantly more diabetics (25%; p<0.001) in the selected study group (data not shown). Median age of our study population was 67 [IQR 49-78] years, 40% were male and 66% had co-existing medical conditions. Of 376 patients included at the Emergency Department, 329 (88%) were hospitalized. None of the patients recruited in primary care were hospitalized. (Table 1 ). Nineteen (5%) of ED patients were admitted to the ICU, of these two died.
( Table 2) .
MR-proADM versus other biomarkers in predicting 30-day mortality
To define the prognostic accuracy of different biomarkers for predicting 30-day mortality, ROC analyses were performed. The AUC for MR-proADM 
MR-proADM and clinical parameters
In addition to 30-day mortality, median MR-proADM level was significantly correlated with bacteraemia (bacteremic versus non-bacteremic patients: tients with a score ≤100 points). Furthermore, MR-proADM levels increased with age and were significantly higher in patients with heart failure and chronic renal insufficiency.
The Kaplan-Meier curves showed no 30-or 90-day mortality in patients with MR-proADM levels in the 1 st quartile (n=123) of the whole group. In the 2 nd quartile (n=124) three events occurred, four in the 3 rd quartile (n=124), and eleven in the 4 th quartile (n=123). All three events in the 2 nd quartile occurred late in current disease episode: day 16, 27 and 33. One event in the 3 rd quartile occurred on day 3, the other three occurred late after disease onset (day 41, 42 and 66). Events in the 4 th quartile occurred primarily in the early stage of current disease episode. This suggests that events in the in the 4 th quartile occur as result of the current active disease (Figure 1 ). The 30-day cumulative survival rate was 1.00 in the 1 st quartile, 0.98 in the 2 nd quartile (log rank p =0.157), 1.00 in the 3 rd quartile (log rank p 1.00) and 0.92 in the 4 th quartile (log rank p =0.001). The 90-day cumulative survival rate was 1.00 in the 1 st quartile, 0.98 in the 2 nd quartile (log rank p =0.083), 0.97 in the 3 rd quartile (log rank p =0.046) and 0.91 in the 4 th quartile (log rank p =0.001).
Discussion
The main finding of the present study is that MR-proADM, determined on first contact in a patient with presumptive fUTI, predicts a complicated course of disease necessitating hospital admission and admission to the ICU, and a worse outcome of infection as reflected by 30-day mortality. MR-proADM Figure 1 . Kaplan-Meier curves of 90-day mortality according to quartiles of mid-regional pro-adrenomedullin (MR-proADM) 5 more accurately predicts outcome than currently used biomarkers. Furthermore, we found significantly higher plasma MR-proADM levels in patients presenting with bacteraemia. Given these characteristics, measurement of MR-proADM in patients with a presumptive diagnosis of fUTI may provide the clinician more accurate guidance than currently applied biomarkers, e.g., with respect to admission of high-risk patients, and thus help focus resources to the patients that need them most.
Strengths of this study are its prospective design in which fUTI patients were (19) .
There are also some limitations. We determined MR-proADM levels once, at first contact with the physician. This precludes the analysis whether a rise or decline in MR-proADM levels correlates to changes in the clinical course of disease, as has been determined for e.g. PCT (20) . However, our findings show that having a single baseline value can provide clinicians guidance in predicting a complicated clinical course at the ED or primary care. This is where patients initially present and decisions have to be made regarding treatment and hospital admission. When interpreting MR-proADM, it should be taken into account that certain patient characteristics like age and heart failure may affect the plasma level of MR-proADM, as well as disease duration before presentation. A technical limitation might be that the measurement of MR-proADM and other biomarkers was done afterwards, and not immediately 'at the bedside'. However, it has been shown that frozen storage and consequent freeze-thaw cycles of blood samples has no influence on the analyte and measured concentration (15;21) . Finally, it should be realized that our findings pertain to fUTI and need be confirmed in other infectious conditions. Of note, similar findings have been made in other infectious states albeit usually in much smaller groups of patients and rarely prospectively (14;22-25) .
We hypothesize that at least two mechanisms might be responsible for the marked increase of MR-proADM in fUTI. In vitro and in vivo studies have shown that the onset of inflammation is accompanied by changes in both ADM and pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1). Plasma ADM levels are markedly increased in patients with septic shock, supporting the hypothesis that pro-inflammatory cytokines augment ADM production and may increase plasma levels of ADM (11;26-28) . However, ADM is also capable of upregulation of interleukine-6
in non-stimulated and LPS-stimulated macrophages, thereby suppressing LPS-induced TNF-α production (29) . This suggests that ADM acts as part of a regulatory loop balancing pro-inflammatory cytokines with its anti-inflammatory actions. Since LPS and cytokine levels were not measured in our study, we cannot refute or confirm this hypothesis. Secondly, a decreased clearance of ADM by the kidneys may be -at least in part -responsible for increased proADM levels in fUTI. This is supported by our data with a higher median MR-proADM in patients with chronic renal insufficiency and studies that have shown a significant correlation between MR-proADM and creatinine levels (14;30) .
In conclusion, we show that MR-proADM has a strong predictive value for 30day mortality in patients with fUTI compared to more conventional biomarkers. Next, studies may wish to confirm the selected cut-off value as a predictor of complicated course and evaluate in daily follow up measurements of MR-proADM the relationship to treatment and clinical recovery. Such studies will establish whether MR-proADM could function as a new prognostic tool for guidance in risk stratification and clinical outcome in patients with fUTI.
